Granules India shines on getting nod from Brazilian Health Regulatory Agency
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Granules India is currently trading at Rs. 299.85, up by 5.05 points or 1.71% from its previous closing of Rs. 294.80 on the BSE.
The scrip opened at Rs. 296.85 and has touched a high and low of Rs. 300.60 and Rs. 295.20 respectively. So far 3035 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 381.25 on 04-Nov-2022 and a 52 week low of Rs. 267.85 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 300.60 and Rs. 290.15 respectively. The current market cap of the company is Rs. 7135.42 crore.
The promoters holding in the company stood at 42.02%, while Institutions and Non-Institutions held 28.03% and 29.95% respectively.
Granules India has received the approval from Brazilian Health Regulatory Agency (ANVISA), for compliance with the guidelines of Good Manufacturing Practices for its Bonthapally facility, located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Hyderabad, Telangana. Bonthapally facility manufactures Active Pharmaceutical Ingredients (API).
Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).
